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Abstract
Purpose—To report the ocular phenotype in patients with autosomal recessive bestrophinopathy
and carriers, and to describe novel BEST1 mutations.
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Methods—Patients with clinically suspected and subsequently genetically proven autosomal
recessive bestrophinopathy underwent full ophthalmic examination and investigation with fundus
autofluorescence imaging, spectral domain optical coherence tomography, electroretinography,
and electrooculography. Mutation analysis of the BEST1 gene was performed through direct
Sanger sequencing.
Results—Five affected patients from four families were identified. Mean age was 16 years
(range, 6–42 years). All affected patients presented with reduced visual acuity and bilateral,
hyperautofluorescent subretinal yellowish deposits within the posterior pole. Spectral domain
optical coherence tomography demonstrated submacular fluid and subretinal vitelliform material
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in all patients. A cystoid maculopathy was seen in all but one patient. In 1 patient, the location of
the vitelliform material was seen to change over a follow-up period of 3 years despite relatively
stable vision. Visual acuity and fundus changes were unresponsive to topical and systemic
carbonic anhydrase inhibitors and systemic steroids. Carriers had normal ocular examinations
including normal fundus autofluorescence. Three novel mutations were detected.
Conclusion—Three novel BEST1 mutations are described, suggesting that many deleterious
variants in BEST1 resulting in haploinsufficiency are still unknown. Mutations causing autosomal
recessive bestrophinopathy are mostly located outside of the exons that usually harbor vitelliform
macular dystrophy–associated dominant mutations.
Keywords
autosomal recessive bestrophinopathy; BEST1 gene; deleterious mutations; vitelliform
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BEST1 (VMD2) is a gene located on the long arm of chromosome 11 (11q12.3) that encodes
for the 585 amino acid transmembrane protein bestrophin 1, located on the basolateral
aspect of retinal pigment epithelial (RPE) cells.1 The exact function of bestrophin 1 is still
not unequivocally characterized, but it is linked to transepithelial chloride flow possibly by
controlling Ca2+ channels in the RPE.1–3 Mutations in BEST1 therefore affect RPE
metabolism, and by consequence outer retinal function with which the RPE is intimately
associated. Over 200 mutations in BEST1 have been identified and published.1,3,4 Mutations
are associated with Best vitelliform macular dystrophy (VMD, MIM 153700), adult-onset
vitelliform macular dystrophy (MIM 608161), retinitis pigmentosa 50 (RP50, MIM 613194),
and autosomal dominant vitreoretinochoroidopathy (MIM 193220). These diseases are all
caused by autosomal dominant mutations. Recently, a phenotype caused by autosomal
recessive mutations in BEST1 was described: autosomal recessive bestrophinopathy (ARB,
OMIM 611809).
Autosomal recessive bestrophinopathy is a rare ocular disease. It was defined by Burgess et
al1 in 2008, although the same condition with compound heterozygous mutations in VMD2
had been described 2 years earlier.5 It results from biallelic mutations in BEST1 and is
characterized by a multifocal vitelliform dystrophy with subretinal fluid. An association
with hypermetropia and angle closure has been described.1 Herein, we review the clinical
features and mutation analysis of four families with ARB.

Materials and Methods
Patients and Clinical Analyses
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All patients underwent a complete ophthalmic examination by a retinal physician. This
included best-corrected visual acuity, cycloplegic refraction, slit-lamp biomicroscopy, and
dilated funduscopy. All patients underwent color fundus photography, fundus
autofluorescence imaging, and spectral domain optical coherence tomography. In addition,
Patient 4 underwent fluorescein and indocyanine green angiography. When possible,
patients had electroretinography and electrooculography performed under the International
Society for Clinical Electrophysiology of Vision standards.6,7 Peripheral blood was drawn
for genetic testing. Patients provided written informed consent for all procedures, which
Retina. Author manuscript; available in PMC 2015 May 09.
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were approved by the Ethics Committees of the sites involved and adhered to the
Declaration of Helskinki (Institutional Review Board protocol #AAAB6560 Columbia
University).
Genetic Analyses
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All 11 exons of BEST1 gene were sequenced by Sanger direct sequencing method to obtain
sequences for all coding sequences, the noncoding Exon 1, and 50bp of adjacent intronic
sequences of each exon. Primer sequences are available on request. Messenger RNA was
isolated from venous blood using QIAamp RNA Blood Mini Kit (QIAGEN Cat. No. 75142)
with a fast spin-column procedure. Genomic DNA is eliminated by pre-treating the RNA
sample with DNase I, Amplification Grade (Invitrogen Cat. No. 18068-015 DNase I
Amplification Grade; Invitrogen, Carlsbad, CA). The primer pair was designed to
encompass BEST1 Exons 1 and 2. Forward primer was in the Exon 1 of BEST1,
5′ACCAGCCTAGTCGCCAGA3′ (1) and the reverse primer in the Exon 2 of BEST1,
5′GCGGATGATGTAGTAGCAGAG3′ (2). The final concentration for each primer was 0.2
μmol. The thermal cycling conditions were established using a ABI 9700 thermocycler
(Applied Biosystems, Foster City, CA). Efficient complementary DNA synthesis was
achieved in a 30-minute incubation at 55° C. Polymerase chain reaction (PCR) amplification
consisted of 40 cycles of 94°C for 15 seconds, 65° C for 30 seconds, and 68°C for 1 minute.
We used 1 cycle 68°C for 5 minutes for final extension.

Results

Author Manuscript

Five patients from four families with genetically confirmed ARB were identified. Mean age
was 16 years (range, 6–42 years). Two patients (Patients 3 and 5) were the product of a
consanguineous marriage. All patients presented with reduced visual acuity and bilateral,
subretinal yellowish deposits within the posterior pole that showed increased
autofluorescence on fundus autofluorescence imaging. On spectral domain optical coherence
tomography, submacular fluid and subretinal changes suggestive of vitelliform material
were present in all patients. In 1 patient (Patient 4), the location of the vitelliform material
was seen to change over a follow-up period of 3 years with relatively stable vision. A
cystoid maculopathy was seen in all but one patient (Patient 5). Visual acuity and fundus
changes were unresponsive to topical and systemic carbonic anhydrase inhibitors and
systemic steroids. Both parents of Patient 3 had normal ocular examinations including
normal 20/20 vision, normal fundus autofluorescence, and a completely normal spectral
domain optical coherence tomography. Clinical features and investigations are described
below and summarized in Figures 1–4 and Tables 1–3.

Author Manuscript

Family 1, Patients 1 and 2
A 11-year-old otherwise healthy white boy presented with a 6-month history of reduced
vision and central scotoma (Figure 1). His vision was 20/25 in both eyes, and there was no
evidence of angle closure. Bilateral, multifocal subretinal hyperautofluorescent yellowish
deposits extended from the posterior poles up to the equator. Cystoid macular edema and
shallow serous macular detachments were present in both eyes. Treatment with topical
nepafenac 0.1% (1 month) and prednisone 10 mg PO (3 weeks) failed to improve vision or

Retina. Author manuscript; available in PMC 2015 May 09.

FUNG et al.

Page 4

Author Manuscript

the fundus appearance. His 7-year-old brother was subsequently found to have almost
identical clinical findings, whereas his 9-year-old sister and parents were unaffected.
Compound heterozygous BEST1 variants were identified in the affected patients. The first
was a novel c.728C>A; p.Ala243Glu missense mutation in Exon 7. In the same codon,
previously reported BEST1 variants include p.Ala243Val8 and p.Ala243Thr.9 Both the
nucleotide and the amino acid are highly conserved in this position of BEST1. All predictive
programs suggest that the variant is disease-causing or disease-damaging. Therefore, it is
highly likely that this variant is deleterious as are (almost) all BEST1 variants implicated in
ARB. The second mutation, the previously described c.598C>T; p.Arg200* mutation,1
generates a stop codon and results in a truncated protein at position 200.
Family 2, Patient 3

Author Manuscript

A 6-year-old asymptomatic, U.S.–born African boy was noted to have poor vision by his
schoolteacher (Figure 2). A history of consanguinity was present in the family, with his
parents being first cousins. Bilateral, multifocal curvilinear subretinal hyperautofluorescent
yellowish deposits were present in both eyes with cystic edema and subretinal fluid at the
maculae. Subfoveal choroidal thicknesses were 586 μm in the right eye and 482 mm in the
left eye. Trials of topical dorzolamide 2% 3 times a day in both eyes (6 weeks),
acetazolamide 500 mg nocte (2 months), and prednisone failed to improve vision or the
clinical appearance. Three years after first presentation, the vision remained stable at 20/80
in both eyes. All other family members were clinically unaffected.

Author Manuscript

A novel, homozygous deleterious mutation was identified in the proband in the in-frame
deletion of 3 nucleotides, c.847_849delTTC, which results in a homozygous deletion of
phenylalanine at position 283, p.Phe283del.
Family 3, Patient 4
A 12-year-old otherwise healthy, emmetropic Puerto Rico–born U.S. boy was noted to have
reduced vision on routine eye examination. Bilateral, confluent curvilinear subretinal
hyperautofluorescent yellowish vitelliform deposits became more multifocal and dispersed
over 3 years of follow-up (Figure 3). Bilateral multifocal serous retinal detachments and
cystic edema involved both maculae. Subfoveal choroidal thickness was 537 μm in the right
eye and 527 μm in the left eye. Oral prednisone 60 mg daily (3 months), topical dorzolamide
2% 3 times a day in both eyes (6 weeks), and oral acetazolamide (6 weeks) were trialed to
reduce the cystoid maculopathy with no clinical response.

Author Manuscript

A previously described10 homozygous c.821C>G; p.Pro274Arg variant was detected. This
variant of a highly conserved nucleotide and an amino acid is predicted to be deleterious by
all predictive programs.
Family 4, Patient 5
A 42-year-old woman whose vision problems started at 5 years of age was recently noticing
deteriorating central vision (Figure 4). She was the product of a first-cousin marriage. A
white-yellow vitelliform lesion was present at the left fovea, and RPE and retinal atrophy
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within the posterior poles. Shallow subretinal but not intraretinal fluid was present at both
maculae. Subfoveal choroidal thickness was 370 μm in both eyes. A trial of oral
acetazolamide 500 mg failed to improve the vision.

Author Manuscript

A splice site variant, c.-29+5G>A (IVS1+5G>A), was identified in Intron 1 of BEST1 in the
donor site of the first untranslated exon. This exon is usually not screened for variants in
patients with BEST1-associated diseases. As shown in Table 3, the variant practically
abolishes the splice donor site as predicted by all programs. To confirm the functional
consequences of this variant, we performed the splicing studies through an “illegitimate
transcript” strategy. Although the BEST1 gene is expressed only in the retinal pigment
epithelium, it can also be detected by PCR at very low levels from other cells, such as the
leucocytes in peripheral blood. We isolated messenger RNA from a blood sample of Patient
5 and performed PCR encompassing two exons. As seen in Figure 5, the messenger RNA of
a normal control produced the expected PCR fragment in the situation where the splicing
had been performed correctly. In this patient, homozygous for the IVS1+5G>A variant, the
expected PCR product of 234bp was not detected and it was clear that the splicing of BEST1
gene was incorrect, very likely resulting in no functional messenger RNA and, consequently,
no BEST1 protein.

Discussion

Author Manuscript

Autosomal recessive bestrophinopathy is a rare disease, with only a few case series
described.1,5,10,12–17 The timing of presentation is variable, with patients as young as 3
years10 and as old as 45 years13 being reported. Patients are typically hyperopic and present
with moderately reduced vision, bilateral multifocal hyperautofluorescent vitelliform lesions
with foveal involvement, and shallow retinal detachment. Scotopic and photopic full-field
electroretinographies usually diminish with age, and the electrooculography shows a
reduced or absent light rise (Arden ratio 1.0).

Author Manuscript

Our patients’ phenotypes are all very consistent with these previous reports of ARB,
although some interesting observations can be made. In one case (Patient 1), the vitelliform
material appeared to emanate from the RPE on spectral domain optical coherence
tomography. In 3 patients (Patients 1, 3, and 4), the retinal architecture was abnormal with
thickening of Band 2 (traditionally described as the inner segment/outer segment junction),
even in extramacular attached retina. Although it would be easy to ascribe this to vitelliform
material, this area of “Band 2” thickening did not uniformly hyperautofluoresce and may
instead represent elongation of degenerate photoreceptors. In four patients (Patients 1–4),
the presence of a cystoid maculopathy was striking. This had been reported
previously10,12,13,16,17 and may represent perturbation of the blood–retinal barrier.
Inflammation is less likely given the lack of anterior chamber or vitreous cells, optic
neuritis, or vasculitis in all these patients. This cystic edema was absent in the eldest patient
(Patient 5, 42 –years old). It is possible that with time, the multifocal vitelliform material in
pediatric cases of ARB resolves. Subfoveal choroidal thickness was measured by enhanced
depth imaging optical coherence tomography in three patients (Patients 3–5), with
thickening in Patient 5. Unfortunately, not only has choroidal thickness not been described
in ARB before, but normative data only apply to adults19 and are lacking in the pediatric
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population. It is therefore difficult to determine if the choroidal thickness was pathologic in
Patients 3 and 4.

Author Manuscript

Patient 4 had a 3-year follow-up and demonstrated dispersion and a change in location of the
vitelliform material from superior to nasal to the optic disks. This is one of the longest
follow-ups of a patient with ARB that we are aware of, and the first to describe fluctuation
and dispersion in appearance. This patient also had indocyanine green angiography, which
has only been described once before in ARB.15 There was bilateral midphase
hyperfluorescence at both maculae, which colocalized with the area of fluorescein leakage.
This may represent leakage of indocyanine green dye into the shallow neurosensory
detachments or choroidal hyperpermeability. Lipofuscin-rich vitelliform material does not
normally stain with indocyanine green dye.20 In VMD, which has similarities to ARB,
small, peripheral hyperfluorescent spots on indocyanine green angiography have been
described,20 and histopathology has shown involvement not only of the retina and RPE but
also of fibrillar material and electron-dense particles on electron microscopy within the
choroid.21,22
Attempts at managing the cystic macular changes with topical and systemic carbonic
anhydrase inhibitors and systemic steroids proved unsuccessful. However, it must be
emphasized that the medications, dosages, and durations were not standardized, and Patient
2 was not prescribed any treatment.

Author Manuscript

We identified 3 novel BEST1 mutations (c.728C>A [p.Ala243Glu] in Family 1, c.
847_849delTTC [p.Phe283-del] in Patient 3, and IVS1+5G>A in Patient 5), suggesting that
many deleterious variants in BEST1 resulting in loss of function are still unknown. It has
been hypothesized that the ARB phenotype is caused by mutations that occur in the
intracellular loop of the protein10 or that the presence of two null alleles lead to disease. We
agree that autosomal recessive mutations in BEST1 that lead to ARB are most likely
deleterious while autosomal dominant mutations in BEST1 lead to VMD because of a
dominant negative effect. Based on our results and reviewing those previously described, we
also suggest that the dominant and recessive mutations mostly do not overlap and that the
recessive mutations are located throughout the gene.

Author Manuscript

Other conditions can mimic the phenotypic appearance of ARB. These include multifocal
Best disease, adult-onset VMD, multifocal pattern dystrophy associated with peripherin/RDS
mutations, acute, exudative polymorphous vitelliform maculopathy, and paraneoplastic
syndromes or metastases.23–26 In addition, chronic, central serous choroidopathy can present
with serous retinal detachments, cystoid maculopathy, and subretinal fibrin, although fibrin
does not hyperautofluoresce. Boon et al23 studied clinical and genetic heterogeneity in 15
patients with a multifocal vitelliform phenotype. Nine of these patients carried a BEST1
mutation and one a peripherin/RDS mutation. Not only were the phenotypic appearance of
patients with BEST1 mutations diverse, but some of the patients without mutations in BEST1
presented with a fundus appearance identical to the patients we describe in this study.
Incorrect initial diagnoses in our patients included acute exudative polymorphous vitelliform
maculopathy, Vogt–Koyanagi–Harada disease, and fundus flavimaculatus. Comprehensive

Retina. Author manuscript; available in PMC 2015 May 09.

FUNG et al.

Page 7

Author Manuscript

screening by sequencing of the entire BEST1 gene is therefore essential for the correct
classification of these patients.
In summary, we report five patients from four families where affected individuals presented
with ARB. Genetic analyses confirmed the disease in all families and showed segregation of
likely deleterious, homozygous, or compound heterozygous mutations in BEST1 with the
disease phenotype. This study highlights several important points for the management of
ARB:

Author Manuscript
Author Manuscript

1.

Visual acuity remains relatively stable, although the fundus vitelliform pattern may
fluctuate and diminish with time

2.

Subretinal fluid and cystoid macular changes associated with ARB do not respond
to topical and systemic carbonic anhydrase inhibitors or systemic steroids

3.

Three of the five mutations were novel, suggesting that many deleterious variants
in BEST1 resulting in loss of function are still unknown

4.

Sequencing of the entire gene is required to avoid missing any BEST1 mutations.
Mutations causing ARB are mostly located outside of the exons that usually harbor
VMD-associated dominant mutations (Exons 2–6 of BEST1)

5.

Mutations causing VMD and ARB rarely overlap. The former have a dominant
negative effect causing disease phenotype in a heterozygous state. The latter delete
the BEST1 protein but do not cause the disease in heterozygosity, because carriers
of recessive BEST1 mutations (all parents and some siblings of ARB cases) have a
normal phenotype

6.

Because the phenotype of ARB may mimic other diseases, molecular genetic
confirmation of mutations in BEST1 is required to confirm the diagnosis.
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Family 1, Patient 1. A 11-year-old otherwise healthy white boy presented with a 6-month
history of reduced vision and central scotoma. A. Color fundus photographs demonstrate
bilateral, multifocal subretinal yellowish deposits within the posterior pole extending up to
the equator. B. There is intense hyperautofluorescence (Topcon TRC-50DX retinal camera;
Topcon America, Paramus, NJ) of the yellowish deposits and moderate
hyperautofluorescence in the areas of subretinal fluid. C. Spectral domain optical coherence
tomography (Topcon 3D-OCT 2000) horizontal scans through the maculae reveal cystoid
macular changes and shallow serous macular detachments in both eyes. There is thickening
and hyperreflectivity at the inner segment/outer segment photoreceptor junction (“Band 2,”
arrows). D. Spectral domain optical coherence tomography horizontal scan through the
superior vascular aracade, 3 months after presentation colocalizes the vitelliform material to
the subretinal space. The material appears to be emanating from the RPE (stars). E. Genetic
screening of the family members confirmed the segregation of the two BEST1 mutations
with the disease.
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Fig. 2.
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Family 2, Patient 3. A 6-year-old asymptomatic, U.S.–born African boy was noted to have
poor vision by his schoolteacher. A. Color montage fundus photographs. In the right eye,
there is subtle vitelliform material nasal to the optic disk. In the left eye, multifocal,
curvilinear subretinal yellowish deposits are seen along the superotemporal arcade. B.
Fundus autofluorescence imaging (Topcon TRC-50DX retinal camera; Topcon America)
demontrates hyperautofluorescence of the vitelliform material in the left eye. C. Enhanced
depth imaging spectral domain optical coherence tomography (Heidelberg Spectralis HRA
+OCT; Heidelberg Engineering Inc, Heidelberg, Germany) demonstrates bilateral shallow
subretinal fluid involving the maculae, a cystoid maculopathy, and subfoveal choroidal
thicknesses of 586 μm in the right eye and 482 μm in the left eye. There is thickening and
hyperreflectivity at the inner segment/outer segment photoreceptor junction (“Band 2,”
arrows). D. The consanguineous parents had normal retinal examinations, 20/20 vision in
both eyes and normal quantitative fundus autofluorescence imaging. Two older brothers and
one sister, who were not available for genetic screening, were visually asymptomatic with
20/20 vision in both eyes.
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Fig. 3.
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Family 3, Patient 4. A 12-year-old otherwise healthy, emmetropic Puerto Rico-born U.S.
boy was noted to have reduced vision on routine eye examination. A. Montage color fundus
photographs at initial presentation. There are bilateral, confluent curvilinear subretinal
yellowish vitelliform deposits superior to the optic disks, along the temporal vascular
arcades and encircling the maculae. B and C. Color fundus photographs 3 years later. The
vitelliform material has become more multifocal and dispersed to involve the nasal retinae.
Visual acuities remained stable at 20/60 in the right eye and 20/70 in the left eye. D. Fundus
autofluorescence imaging (Topcon TRC-50DX retinal camera; Topcon America)
demonstrates hyperautofluorescence of the vitelliform material. E. On fluorescein
angiography (Topcon TRC-50DX; 61 seconds for the right eye, 92 seconds for the left eye),
there is widespread diffuse hyperfluorescence consistent with pooling in the subretinal space
and staining of the subretinal yellowish deposits. F. Indocyanine green angiography (Topcon
TRC-50DX; 11 minutes 43 seconds for the right eye, 12 minutes 7 seconds for the left eye)
demonstrates bilateral midphase hyperfluorescence at the maculae. G. On spectral domain
optical coherence tomography (Spectral OCT/SLO; OPKO Instrumentation, Miami, FL),
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there are bilateral, multifocal serous retinal detachments involving the maculae and cystoid
changes in the macula. There is thickening and hyperreflectivity at the inner segment/outer
segment photoreceptor junction (“Band 2”, arrows). Subfoveal choroidal thickness measured
537 μm in the right eye and 527 μm in the left eye with enhanced depth imaging.
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Fig. 4.

Family 4, Patient 5. A 42-year-old woman whose vision problems started at 5 years of age
was recently noticing deteriorating central vision. She was the product of a first-cousin
marriage. A. Color fundus photographs showing a white–yellow vitelliform lesion at the left
fovea. There is RPE and retinal atrophy within the posterior poles. B. Fundus
autofluorescence imaging shows bilateral discrete patches of hypoautofluorescence. The
vitelliform lesion at the left fovea hyperautofluoresces. C. On spectral domain optical
coherence tomography (Heidelberg Spectralis HRA+OCT; Heidelberg Engineering Inc),
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shallow subretinal fluid is seen at both maculae but not cystoid maculopathy. The subretinal
vitelliform deposit is seen in the left eye. Subfoveal choroidal thickness measured 370 μm in
both eyes with enhanced depth imaging.
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Fig. 5.
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Analysis of splicing of the BEST1 gene in Patient 5. Complementary DNA from Patient 5,
harboring the IVS1+5G>A variant (A, Lane 1), and from a normal control individual (A,
Lane 2) was amplified by primers located in Exons 1 and 2 of the BEST1 gene.
Amplification of the cDNA of a normal control produced the expected PCR fragment of
234bp (A, Lane 2). This 234bp PCR fragment corresponds to the correctly spliced fragment
containing Exons 1 and 2, as shown in the dotted line above in (B). Amplification of the
cDNA of the patient homozygous for the IVS1+5G>A variant did not yield the expected
PCR product because the first intron (IVS1) was not spliced out, resulting in a large 1538bp
PCR product which includes the entire IVS1 (A, Lane 1; B, line below). Lanes 3 and 4 show
DNA size standards. cDNA, complementary DNA.
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5 (42/F)

4

Caucasian

Latino

African

White

White

Ethnicity

3 months

3 years

3 years

0 months

4 months

Follow-up Duration

D, diopters; OD, right eye; OS, left eye; OU, both eyes.

4 (12/M)

3

2 (7/M)

1

3 (6/M)

1 (11/M)

1

2

Patient
(Age, Years/Gender)

Family

20/150 OU

20/90 OU

20/80 OD,
20/100 OS

20/25 OU

20/22 OU

Snellen BestCorrected
Visual Acuity
on Presentation

20/150 OU

20/60 OD,
20/70 OS

20/80 OU

20/25 OU

20/50

Snellen BestCorrected
Visual Acuity
at Last Visit

+10.00D OD, +10.00D OS

Emmetropic axial lengths:
21.6 mm OD, 21.3 mm OS

+4.00 OD, +4.25 D OS

Unknown

−2.50 D OD, −2.75 D OS

Refraction, Diopters
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Clinical Features of Patients With ARB

Shallow

Open

Open

Open

Open

Anterior Chamber Angle

Left foveal vitelliform
deposit

Bilateral multifocal
vitelliform deposits

Bilateral multifocal
vitelliform deposits

Bilateral multifocal
vitelliform deposits

Bilateral multifocal
vitelliform deposits

Fundus Appearance
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N

Y

Y

Y

Y

CME

ERG not performed on the day of EOG. The patient will not have separate ERG done.

Bilateral discrete patches of hypoautofluorescence, with
hyperautofluorescence at the left macula

Hyperautofluorescent vitelliform material

Hyperautofluorescent vitelliform material

Hyperautofluorescent vitelliform material

Hyperautofluorescent vitelliform material

FAF

Y

Y

Y

Y

Y

SRF

370mm OD, 370mm OS

537 μm OD, 527 μm OS

596 μm OD, 482 μm OS

Unknown

Unknown

Subfoveal Choroidal Thickness

OCT

Diminished scotopic and
photopic ffERG

Diminished scotopic and
photopic ffERG

Extinguished scotopic and
photopic ffERG

Arden index: 1.55 OD, 1.67 OS

Failed recording‡

Arden index: 1.0 OU

Not performed

Arden index: 2.1 OD, 2.6 OS

Not performed*
Not performed†

EOG

ERG

EOG, electrooculography; ERG, electroretinography; FAF, fundus autofluorescence; OCT, optical coherence tomography; OD, right eye; OS, left eye; OU, both eyes; CME, cystoid macular edema; SRF,
subretinal fluid.

EOG recordings were performed but failed. The patient is not capable of returning for new EOG testing.

‡

ERG and EOG not performed because of incapacity of the patient to come in to have the International Society for Clinical Electrophysiology of Vision recordings performed.

†

*
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2
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1
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Author Manuscript

Investigations of Patients With ARB

Author Manuscript

Table 2
FUNG et al.
Page 17

Retina. Author manuscript; available in PMC 2015 May 09.

Author Manuscript

Author Manuscript
c.821C>G

IVS1+5G>A

3/4 (Homozygous mutation)

4/5 (Homozygous mutation)

N/A

p.Pro274Arg

p.Phe283del

Moderately conserved nucleotide
(phyloP: 1.42)

Highly conserved nucleotide (phyloP:
5.61); highly conserved amino acid
(up to C. elegans)

Highly conserved amino acid (up to
C. elegans)

cDNA, complementary DNA; SIFT, sorting intolerant from tolerant; N/A, not applicable.

Mutations in bold are novel mutations.

c.847_849del

Moderately conserved nucleotide
(phyloP: 2.95); moderately conserved
amino acid (up to Tetraodon)

p.Arg200*

c.598C>T

2/3 (Homozygous mutation)

Highly conserved nucleotide (phyloP:
5.77); highly conserved amino acid
(up to C. elegans)

p.Ala243Glu

c.728C>A

Conservation

1/1 and 2 (Compound
heterozygous mutations)

Protein Position

cDNA Position

Family/Patient (Remark)

N/A

Deleterious
(score: 0.00,
median: 3.07)

N/A

N/A

Deleterious
(score: 0.01,
median: 3.07)

SIFT
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In Silico Analysis of the Five BEST1 Mutations Found in Four Patients/Families

N/A

Probably damaging,
score: 1.000
(sensitivity: 0.00;
specificity: 1.00)

N/A

N/A

Probably damaging,
score: 1.000
(sensitivity: 0.00;
specificity: 1.00)

PolyPhen-2

N/A

Disease-causing
(P: 1.0)

N/A

N/A

Disease-causing
(P: 1.0)

Mutation Taster

N/A

N/A

Splicing

MaxEnt:
−100.0%,
NNSPLICE:
−97.7%

N/A

MaxEnt: 0.0%,
NNSPLICE:
0.0%
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